Suppr超能文献

视力评估的前瞻性研究:临床实践中Snellen视力表与ETDRS视力表的比较(一篇美国眼科学会论文)

Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis).

作者信息

Kaiser Peter K

机构信息

The Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, USA.

出版信息

Trans Am Ophthalmol Soc. 2009 Dec;107:311-24.

Abstract

THE PURPOSE OF THIS STUDY WAS TWOFOLD

first, to prospectively compare visual acuity (VA) scores obtained with Snellen charts versus Early Treatment Diabetic Retinopathy Study (ETDRS) charts in a "real world" retinal practice, and second, to see if there was a difference in visual acuity measurements obtained with ETDRS charts starting at 4 or 2 meters.

METHODS

Prospective, consecutive evaluation of patients who underwent best-corrected visual acuity testing of their right eye performed at a single seating by the same experienced, certified vision examiner in the same room with standardized low light conditions using a projected Snellen chart at 20 feet, and two different back-illuminated ETDRS charts placed 4 and 2 meters from the patient.

RESULTS

One hundred sixty-three eyes were included in the study. The mean Snellen VA was 0.67 logMAR (20/94), ETDRS VA at 4 meters was 0.54 logMAR (20/69), and ETDRS VA at 2 meters was 0.51 logMAR (20/65). The mean difference was 6.5 letters better on the ETDRS chart (P=.000000001). As the VA worsened, there was increased variability between the charts and the mean discrepancy between charts also increased. Subgroup analysis revealed the greatest difference between charts was in the poor vision subgroup (<20/200) with a difference of 0.2 logMAR (10 letters; P=.0000002). Patients with exudative age-related macular degeneration (AMD) had the greatest disparity on vision testing, but patients with dry AMD and diabetic retinopathy also exhibited significant differences.

CONCLUSIONS

Visual acuity scores were significantly better on ETDRS charts compared to Snellen charts. The difference was greatest with poor visual acuity (<20/200) and in patients with exudative AMD. Thus, caution should be exercised when comparing data using the different charts.

摘要

本研究有两个目的

第一,在“现实世界”的视网膜诊疗实践中,前瞻性地比较使用斯内伦视力表与早期糖尿病性视网膜病变研究(ETDRS)视力表所获得的视力(VA)评分;第二,观察从4米或2米处开始使用ETDRS视力表所获得的视力测量结果是否存在差异。

方法

对患者进行前瞻性、连续性评估,由同一位经验丰富、具备资质的视力检查者在同一房间、标准化低光照条件下,使用20英尺处的投影斯内伦视力表,以及放置在距患者4米和2米处的两种不同的背部照明ETDRS视力表,对其右眼进行最佳矫正视力测试。

结果

163只眼纳入研究。平均斯内伦视力为0.67 logMAR(20/94),4米处的ETDRS视力为0.54 logMAR(约20/69),2米处的ETDRS视力为0.51 logMAR(约20/65)。ETDRS视力表上的平均差异要好6.5个字母(P = 0.000000001)。随着视力变差,两种视力表之间的变异性增加,且视力表之间的平均差异也增大。亚组分析显示,视力表之间差异最大的是视力差的亚组(<20/200),差异为0.2 logMAR(10个字母;P = 0.0000002)。渗出性年龄相关性黄斑变性(AMD)患者在视力测试中的差异最大,但干性AMD和糖尿病性视网膜病变患者也表现出显著差异。

结论

与斯内伦视力表相比,ETDRS视力表上的视力评分明显更好。视力差(<20/200)的患者以及渗出性AMD患者的差异最大。因此,在使用不同视力表比较数据时应谨慎。

相似文献

2
3
Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials.
Ophthalmol Retina. 2021 Mar;5(3):224-233. doi: 10.1016/j.oret.2020.04.011. Epub 2020 Apr 23.
5
An innovative visual acuity chart for urgent and primary care settings: validation of the Runge near vision card.
Eye (Lond). 2019 Jul;33(7):1104-1110. doi: 10.1038/s41433-019-0372-8. Epub 2019 Feb 21.
9
Visual Acuity Testing Using a Random Method Visual Acuity Application.
Telemed J E Health. 2016 Mar;22(3):232-7. doi: 10.1089/tmj.2015.0073. Epub 2015 Aug 17.
10

引用本文的文献

2
Effect of extracts in the prevention of posterior capsule opacification after cataract surgery: A randomized clinical trial.
Oman J Ophthalmol. 2025 Jun 24;18(2):126-132. doi: 10.4103/ojo.ojo_311_21. eCollection 2025 May-Aug.
3
Choosing wisely: Improving decision-making for deployment of diagnostics in primary care settings.
J Family Med Prim Care. 2025 May;14(5):1769-1780. doi: 10.4103/jfmpc.jfmpc_1455_24. Epub 2025 May 31.
5
Validation and evaluation of visual acuity and contrast sensitivity with a new digital device: OPTOTAB®.
Ophthalmic Physiol Opt. 2025 Sep;45(6):1302-1316. doi: 10.1111/opo.13536. Epub 2025 Jun 13.
6
Obstacle Circumvention Strategies During Omnidirectional Treadmill Walking in Virtual Reality.
Sensors (Basel). 2025 Mar 8;25(6):1667. doi: 10.3390/s25061667.
10
Visual-somatosensory integration as a novel behavioral marker of amyloid pathology.
Alzheimers Dement. 2025 Mar;21(3):e14561. doi: 10.1002/alz.14561.

本文引用的文献

1
Uniformity of visual acuity measures in published studies.
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4321-7. doi: 10.1167/iovs.07-0511.
2
A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.
Ophthalmology. 2008 Sep;115(9):1447-9, 1449.e1-10. doi: 10.1016/j.ophtha.2008.06.015. Epub 2008 Jul 26.
3
Change of visual acuity recording methods in clinical studies across the years.
Ophthalmologica. 2008;222(3):173-7. doi: 10.1159/000126080. Epub 2008 May 22.
4
Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
Am J Ophthalmol. 2008 Feb;145(2):249-256. doi: 10.1016/j.ajo.2007.09.031. Epub 2007 Dec 11.
5
6
Treatment of choroidal neovascularization using intravitreal bevacizumab.
Acta Ophthalmol Scand. 2007 Aug;85(5):526-33. doi: 10.1111/j.1600-0420.2007.00895.x. Epub 2007 May 18.
7
Comparison of logMAR ETDRS chart and a new computerised staircased procedure for assessment of the visual acuity of children.
Ophthalmic Physiol Opt. 2006 Nov;26(6):597-601. doi: 10.1111/j.1475-1313.2006.00407.x.
8
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
N Engl J Med. 2006 Oct 5;355(14):1432-44. doi: 10.1056/NEJMoa062655.
9
Ranibizumab for neovascular age-related macular degeneration.
N Engl J Med. 2006 Oct 5;355(14):1419-31. doi: 10.1056/NEJMoa054481.
10
Ranibizumab: Phase III clinical trial results.
Ophthalmol Clin North Am. 2006 Sep;19(3):361-72. doi: 10.1016/j.ohc.2006.05.009.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验